Market News

Transaction is expected to close during Q4 2017, before which a new trade name will be selected for the Business.

Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.

Company also becomes the first solution provider to achieve 100 pharmaceutical and contract manufacturers live and ready for serialization.

Small nimble biotechs to introduce a ‘golden age’ of next generation therapies such as CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors.

Company alleges infringement of two patents.

Investment will increase the company's flexibility in meeting both existing and future customer demands.

Project also includes reconfigure the existing small-scale manufacturing area providing a single high-containment building to support early-stage development and manufacturing.

The company's NanoTherm therapy makes it possible to combat the tumour from within, while sparing surrounding healthy tissue.

14 new injection-molding machines and significant increase in efficiency and energy savings.

Contract dispute relates to an agreement entered into among Endo International, Penwest Pharmaceuticals and Impax.

SP Scientifc's ControLyo Central is a suite of online resources to help freeze dried parenterals manufacturers.

Federal judge enters consent decree against outsourcing facility Isomeric Pharmacy Solutions.

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations complements Captek’s offerings.

Life-extending pancreatic cancer medicine to be made available immediately on the NHS.

Bolt-on acquisition adds value to other areas of Lonza’ business, including Health & Nutrition ingredients and excipients.

Romaco will additionally show Innojet process technology and Kilian services at POWTECH.

Gains full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.

EP Vantage releases half-year reviews of pharma & biotech and medtech performance.

The launch represents a major step towards therapeutic use of CRISPR.

Baxter plans to invest in further increasing Claris Injectables’ capacity and capabilities, including adding new aseptic manufacturing and lyophilization.

Company can now offer solutions for serialized receiving, picking, shipping, returns, deactivation, aggregation, de-aggregation, label printing and tag management of pharmaceutical products.

Guide aims to help the operator understand the complex protocols and heavily regulated procedures associated with pharmaceutical cleanrooms.

The merger enables STA to advance NCEs from pre-clinical stage to New Drug Application and to market faster and more efficiently for pharma and biotech customers.

Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.

Dalton Pharma Services is preparing glass vials in three varying dose formulations for the clinical kits needed to support the Phase I safety trial for AB569 at the CVAMC later this year.

Collaboration aims to maximize the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumor types.

The new facilities enable to company to further grow and flourish.

The mPath bioreactor control system is the first to be developed and delivered by a technology supplier specifically for their product line, allowing full access to bioreactor capabilities that current commercial solutions cannot provide.

The CPHI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters.

Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola.

Dermatology unit is rebranded Ortho Dermatologics.

Company launches Ibex innovation in biological development and manufacturing.

Thermo's Samco Clicktainer vials provide secure and reliable sample collection and transport.

First generic prequalification for sofosbuvir tablets.

New approval for treatment of active psoriatic arthritis (PsA).

Vertex now has worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

AI thought to have massive potential to reduce the cost associated with the discovery of new drugs.

40% of industry professionals admit they are not clear about the global requirements for serialization.

STA will provide supplies of certain starting and intermediate materials for the recently launched Zejula.

The biosimilar's list price will represent a 35% discount to the current list price of Remicade.

NKTR-358 has the potential to treat a number of autoimmune and other chronic inflammatory conditions.

The approval marks the first subcutaneous self-injection treatment option for patients with systemic lupus erythematosus.

Expansion will triple capacity, add nearly 300 new jobs.

Collaborations result in development of Corning Valor Glass.

GMP Manufacturing line industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.

Goal of the collaboration is to identify therapies and diseases for which there is a high need for pediatric-friendly formulations.

IHAT, a novel synthetic material, is a commercially viable alternative to ferrous salts for iron supplementation.

With support from the CRO, TopiVert has been able to accelerate scale-up and produce GMP batches, which are now being used in clinical trials.

Company announces investments, the sale of several products and a proposal to close a UK manufacturing site.

Overseas buyers at CPHI Korea double in the past 2 years.

Investment follows demand for the company's AseptiSafe and PharmaSafe product ranges, which transfer APIs in small- and large-scale pharmaceutical manufacturing environments.

Nerlynx is the first extended adjuvant therapy for patients with HER2-positive breast cancer.

Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.

Company has experienced double digit growth across its automation, MES and managed services offering.

The service offers quick and efficient path from late-stage discovery to Phase I clinical trials.

Company expects to launch by the end of the year.

Company expects to supply up to 40 million doses across both vaccines for the US market in the 2017-18 season.

The system's new, variable transport system avoids bottlesnecks or delays in workflow.

Company to invest €90 million and cut 200 jobs.

Patients in Scotland will now join those in England and Wales and be able to benefit from this potentially life-extending immunotherapy on the NHS.

Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio.

Cobalt's portfolio of solutions accelerates entry into high-growth Raman spectroscopy market and expands Agilent’s value proposition for pharmaceutical and biopharma customers.

The 2017 awards include eight new categories - celebrating outstanding achievements in the pharma industry.

Selexipag is an innovative, oral treatment that specifically targets the prostacyclin pathway.

NEXUS 17 attendees claim the greatest serialization challenge thus far has been line vendors’ inability to deliver a solution on time and within scope.

Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.

The new 5-axis machine will speed up the production and delivery of larger diameter valves up to 350 mm.

IH-TMS Tool Management System and the company's latest tool coating solutions interest exhibition visitors.

Acquisition create leading integrated solutions provider to the global pharma and consumer healthcare industries.

Company has immediately initiated commercialization activities.

Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis.

Pharma clients now have direct and immediate access to a fully compliant safety database without needing to invest in their own system or use an interim solution to ensure compliance.

Brilliance tubes provide a user-friendly and attractive all-in-one solution.

First shipment of BIOCAD’s Acellbia to India is scheduled for September 2017.

Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Idifarma, a Spanish CDMO, has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.

In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies.

Three new TurboVap evaporation systems increase laboratory reliability.

Developed to support assay development and validation for detection of anti-drug antibodies.

Pre-clinical collaboration focused on up to 10 targets nominated by GSK.

Investments in commercial and development spray drying, and flexible manufacturing solutions.

Strengthens leadership in rare blood disorders with first-in-class candidate to treat cold agglutinin disease, a chronic autoimmune hemolytic anemia with no approved therapies.

The Chaim Sheba Medical Center now offers the hydrogel spacer to reduce side-effects during prostate cancer radiation therapy.

Company's modification makes the SPU 2000 a more cost effective laboratory tool.

New world-scale ibuprofen production plant in Ludwigshafen; additional capacity expansion of ibuprofen plant in Bishop, Texas.

Two new biosimilar medicines available to treat patients with specific blood cancers and a range of inflammatory condition.

Agreement concerns an existing inhaled combination therapy for asthma and COPD delivered using a pMDI.

Novel approach capitalises on commonality across pathogens.

New offering restores lipid layer and brings hydration to all three layers of tear film damaged by Dry Eye.

Innova’s range of antibody and protein labeling products and services ideally complements SYGNIS’ customer base and existing genomics and proteomics portfolio.

The CDMO is now approved to manufacture medicinal products for the US, Europe and Japan.

Resourcing the deployment of serialization systems and processes also cited as a significant barrier to compliance with European FMD,

US business will be organized into two entities - a US Generics Division and a US Injectables Division.

Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multi-national company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular ...

The addition enables the CDMO to scale-up early-phase bench top processes to support later stage clinical development and niche, low volume manufacturing requirements.

Arcinova has invested in a Uniqsis FlowSyn continuous flow reactor enabling them to develop and simplify the scale-up of a challenging API batch process.

Compared with other small-scale R&D freeze dryers, the LyoCapsule lyophilizer is the only system that can monitor and independently control the wall temperature via use of the center vial product temperature.

The manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the new plant.

Compounded Sodium Bicarbonate PF 8.4% 50mEq per syringe is expected to help alleviate chronic drug shortage impacting the nation's hospitals.

The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

iOnctura is set up to develop a pipeline of assets targeting immunosuppression in the tumour microenvironment.

Actelion will now become part of the Janssen Pharmaceutical Companies of J&J.

Sandoz now has four biosimilars approved in Europe - more than any other company.

Company shifts manufacturing focus in Ireland to reflect growing biologics portfolio with ongoing investment in Cruiserath biologics facility.

Delegates at the recent FlyPharma Conference pick out collaboration as their main goal for the coming year.

Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently.

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases.

Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine.

Extends EMEA sales team with addition of two new regional sales leaders in DACH and Southern Europe regions.

Enables labs around the world to generate more useful information from complex proteins, antibodies, polypeptides and polysaccharides.

Company adds fifth building in Southern California.

Company's CFO leaves to join another biopharma company.

Investment allows company to increase its capacity to handle E&L projects for applications including container testing, medical device evaluation and testing equipment used in pharmaceutical production.

Argus improves the quality and timeliness of safety case processing and reporting, and reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.

Espranor represents the first major advance available in opioid substitution therapy for 10 years.

Application "addresses a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients."

Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatit.is C

As of today, all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s child-resistant feature.

Investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities throughout the company's global facilities.